Prevention of infection in immunocompromised hosts

  • Gary A. Noskin
Part of the Cancer Treatment and Research book series (CTAR)


Infections are a significant cause of morbidity and mortality in patients with neoplastic diseases. In addition, for some malignancies an important factor that limits the ability to administer cytotoxic chemotherapy is the risk of infection. This risk varies among patients based on their underlying disease and host defenses. Neutropenia is the most common host factor that predisposes patients to infection. Other important factors that increase the risk of infection include: defects in cell-mediated and humoral immunity, impaired mucosal or skin integrity, obstruction by mass lesions, and intravascular devices.


Fungal Infection Acute Leukemia Neutropenic Patient Allogeneic Bone Marrow Antifungal Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clift RA, Buckner CD, Fefer A, et al. Infectious complications of marrow transplantation. Transpl Proc 1974;6:389–393.Google Scholar
  2. 2.
    Watson JG. Problems of infection after bone marrow transplantation. J Clin Pathol 1983;36:638–692.Google Scholar
  3. 3.
    Garner JS, Favero MS. CDC guidelines for handwashing and hospital environmental control. Infect Control 1986;7:231–235.PubMedGoogle Scholar
  4. 4.
    Bodey GP, Buckley M, Satha YS, Freidrich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328–340.PubMedGoogle Scholar
  5. 5.
    Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994;19(Suppl. 1):S8–S13.PubMedGoogle Scholar
  6. 6.
    Morris JG Jr., Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250–259.PubMedGoogle Scholar
  7. 7.
    Noskin GA, Cooper I, Peterson LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995;155:1445–1447.PubMedCrossRefGoogle Scholar
  8. 8.
    Nauseef WM, Maki DG. A study of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981;304:448–453.PubMedCrossRefGoogle Scholar
  9. 9.
    Schimpff SC, Hahn DM, Brouillet MD, Young VM, Fortner CL, Wiernik PH. Comparison of basic prevention techniques, with standard room reverse isolation or with reverse isolation plus added filtration. Leuk Res 1978;2:231–240.CrossRefGoogle Scholar
  10. 10.
    Remington JS, Schimpff SC. Please don’t eat the salads. N Engl J Med 1981;304:433–435.PubMedCrossRefGoogle Scholar
  11. 11.
    Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocyte leukemia patients. Cancer 1973;32:1490–1498.PubMedCrossRefGoogle Scholar
  12. 12.
    Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant recipients. A prospective study. Ann Intern Med 1978;89:893–901.PubMedGoogle Scholar
  13. 13.
    Levine AS, Siegel SE, Schreiber AD, et al. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973;288:477–483.PubMedCrossRefGoogle Scholar
  14. 14.
    Schimpff SC, Green WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351–358.PubMedGoogle Scholar
  15. 15.
    Van der Waaij D, Berghuis-de Vries JM. Selective elimination of Enterobacteriaceae species from the digestive tract in mice and monkeys. J Hyg (Camb) 1974;72:205–211.Google Scholar
  16. 16.
    Van der Waaij D, Berghuis-de Vries JM. Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Camb) 1974;72:379–387.Google Scholar
  17. 17.
    Hughes WT, Kuhn S, Chaudhry SC, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419–1426.PubMedCrossRefGoogle Scholar
  18. 18.
    Enno A, Catovsky D, Darrell J, Goldman JM, Hows J, Galton DAG. Co-trimazole for prevention of infection in acute leukaemia. Lancet 1978;2:395–397.PubMedCrossRefGoogle Scholar
  19. 19.
    Starke ID, Donnelly P, Catovsky D, et al. Co-trimazole alone for prevention of bacterial infection in patients with acute leukaemia. Lancet 1982;l:5–9.CrossRefGoogle Scholar
  20. 20.
    de Jongh CA, Wade JC, Finley RS, et al. Trimethoprim/sulfamethoxazole versus placebo: A double blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol 1983;l:302–307.Google Scholar
  21. 21.
    Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann Intern Med 1981;95:555–559.PubMedGoogle Scholar
  22. 22.
    Gurwith MJ, Brunton JL, Lank BA, Harding GK, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytic patients. Am J Med 1979;66:248–256.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiser B, Lange M, Fialk MA, Singer C, Szatrowski TH, Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation therapy for acute leukemia: A controlled trial. Ann Intern Med 1981;95:436–438.PubMedGoogle Scholar
  24. 24.
    Wade JC, de Jongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: Trimethoprim-sulfamethoxazole vs. nalidixic acid. J Infect Dis 1983;147:624–634.PubMedGoogle Scholar
  25. 25.
    EROTC. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EROTC International Antimicrobial Therapy Project Group. J Infect Dis 1984;150:372–379.Google Scholar
  26. 26.
    Verhoef J. Prevention of infection in the neutropenic patient. Clin Infect Dis 1993;17(Suppl. 2):S359–S367.PubMedGoogle Scholar
  27. 27.
    Hathorn JW. Critical appraisal of antimicrobial for prevention of infection in immunocompromised hosts. Hematol Oncol Clin North Am 1993;7:1051–1099.PubMedGoogle Scholar
  28. 28.
    Carratalá J, Fernádez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557–560.PubMedGoogle Scholar
  29. 29.
    Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1–7.PubMedGoogle Scholar
  30. 30.
    Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987;106:7–11.PubMedGoogle Scholar
  31. 31.
    Rozenberg-Arska M, Dekker A, Verdonck, Verhoef J. Prevention of bacteremia caused by a-hemolytic streptococci by roxithromycin (RU-28, 965) in granulocytopenic patients receiving ciprofloxacin. Infection 1989;17:240–244.PubMedCrossRefGoogle Scholar
  32. 32.
    GIMEMA Infection Program. Prevention of bacterial infections in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991;115:7–12.Google Scholar
  33. 33.
    Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial. J Clin Oncol 1995;13:239–250.PubMedGoogle Scholar
  34. 34.
    Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994;12:1005–1011.PubMedGoogle Scholar
  35. 35.
    Imrie KR, Prince HM, Couture F, Brandwein JM, Keating A. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: Ciprofloxacin versus co-trimazole. Bone Marrow Transplant 1995 15:267–270.PubMedGoogle Scholar
  36. 36.
    Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/ polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1990;88: 36–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Liang RH, Yung RW, Chan TK, et al. Ofloxacin versus co-trimazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 1990;34:215–218.PubMedGoogle Scholar
  38. 38.
    Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995;1995:907–912.Google Scholar
  39. 39.
    Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123:205–215.PubMedGoogle Scholar
  40. 40.
    Attal M, Schlaifer D, Rubie H, et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: A prospective, randomized trial. J Clin Oncol 1991;9:865–870.PubMedGoogle Scholar
  41. 41.
    Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681–687.PubMedGoogle Scholar
  42. 42.
    Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Management of emerging fluoroquinolone resistance in Pseudomonas aeruginosa: Outcome of focusing institutional fluoroquinolone use in a referral medical center. Clin Infect Dis, in press.Google Scholar
  43. 43.
    Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731–740.PubMedGoogle Scholar
  44. 44.
    Ezdinli EZ, O’Sullivan DD, Wasser LP, Kim U, Stutzman L. Oral amphotericin for candidiasis in patients with hematologic neoplasms. JAMA 1979;242:258–260.PubMedCrossRefGoogle Scholar
  45. 45.
    Carpentieri U, Haggard ME, Lockhart LH, Gustavson LP, Box QT, West EF. Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia. J Pediatr 1978;92:593–595.PubMedCrossRefGoogle Scholar
  46. 46.
    DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982;50:2780–2784.PubMedCrossRefGoogle Scholar
  47. 47.
    Jones PG, Kauffman CA, McAuliffe LS, Liepman MK, Bergman AG. Efficacy of ketoconazole v. nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 1984;144:549–551.PubMedCrossRefGoogle Scholar
  48. 48.
    Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintilliani R. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984;144:290–293.PubMedCrossRefGoogle Scholar
  49. 49.
    Cuttner J, Troy KM, Funaro L, Brenden R, Bottone EJ. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Am J Med 1986;81:771–774.PubMedCrossRefGoogle Scholar
  50. 50.
    Wingard JR, Vaughn WP, Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized double-blind placebo-controlled trial of intravenous miconazole. Am J Med 1987;83:1103–1110.PubMedCrossRefGoogle Scholar
  51. 51.
    Fainstein V, Bodey GP. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 1980;93:432–433.PubMedGoogle Scholar
  52. 52.
    Hansen RM, Reinerio N, Sohnle PG, et al. Ketoconazole in the prevention of candidiasis in patients with cancer. Arch Intern Med 1987;147:710–712.PubMedCrossRefGoogle Scholar
  53. 53.
    Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1257–1263.PubMedGoogle Scholar
  54. 54.
    Vogler WR, Malcolm LG, Winton EF. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest 1987;5:267–273.PubMedCrossRefGoogle Scholar
  55. 55.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.PubMedCrossRefGoogle Scholar
  56. 56.
    Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.PubMedGoogle Scholar
  57. 57.
    Winston DJ, Chandrashekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with leukemia. Ann Intern Med 1993:118:495–503.PubMedGoogle Scholar
  58. 58.
    Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasms. J Infect Dis 1995;172:1035–1041.PubMedGoogle Scholar
  59. 59.
    Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with hematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3–11.PubMedCrossRefGoogle Scholar
  60. 60.
    Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973–984.PubMedCrossRefGoogle Scholar
  61. 61.
    Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J Antimicrob Chemother 1991;27:369–376.PubMedCrossRefGoogle Scholar
  62. 62.
    Thunnissen PLM, Sizoo W, Hendricks WDH. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991;39:S4–91.Google Scholar
  63. 63.
    Todeschini G, Murari C, Bonesi A, et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;12:614–618.PubMedCrossRefGoogle Scholar
  64. 64.
    Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(Suppl. 1):S94–S99.PubMedGoogle Scholar
  65. 65.
    Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353–358.PubMedCrossRefGoogle Scholar
  66. 66.
    Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891–897.PubMedGoogle Scholar
  67. 67.
    Riley DK. Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509–514.PubMedCrossRefGoogle Scholar
  68. 68.
    O’Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994;12:827–834.PubMedGoogle Scholar
  69. 69.
    Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63–67.PubMedCrossRefGoogle Scholar
  70. 70.
    Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73:229–235.PubMedCrossRefGoogle Scholar
  71. 71.
    Straus SE, Seidlin M, Takiff H, Jacobs D, Bowden D, Smith HA. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med 1984;100:522–524.PubMedGoogle Scholar
  72. 72.
    Sempere A, Sanz GF, Senet L, et al. Long-term acyclovir prophylaxis for the prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992;10:495–498.PubMedGoogle Scholar
  73. 73.
    Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1993;147:737–743.Google Scholar
  74. 74.
    Committee on Infectious Diseases. Recommendations for the use of a live attenuated varicella vaccine. Pediatrics 1995;95:791–795.Google Scholar
  75. 75.
    Gershon AA, Steinberg SP. Persistence of immunity of varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989;320:892–897.PubMedCrossRefGoogle Scholar
  76. 76.
    Zaia JA. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin Infect Dis 1993;17(Suppl. 2):S392–399.PubMedGoogle Scholar
  77. 77.
    Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70–75.PubMedCrossRefGoogle Scholar
  78. 78.
    Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European acyclovir for CMV prophylaxis study group. Lancet 1994;343:749–753.PubMedCrossRefGoogle Scholar
  79. 79.
    Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995;172:939–943.PubMedGoogle Scholar
  80. 80.
    Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV study group. N Engl J Med 1991;324:1005–1011.PubMedCrossRefGoogle Scholar
  81. 81.
    Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601–1607.PubMedCrossRefGoogle Scholar
  82. 82.
    Atkinson K, Downs K, Golenia M, et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection. Br J Haematol 1991;79:57–62.PubMedGoogle Scholar
  83. 83.
    Goodrich JM, Bowden RA, Fisher L, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173–178.PubMedGoogle Scholar
  84. 84.
    Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179–184.PubMedGoogle Scholar
  85. 85.
    Edman JC, Kovac JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334:519–522.PubMedCrossRefGoogle Scholar
  86. 86.
    Jackson HC, Colthurst D, Hancock V, Marriott MS, Tuite MF. No detection of characteristic fungal protein elongation factor EF-3 in Pneumocystis carinii. J Infect Dis 1991;163:675–677.PubMedGoogle Scholar
  87. 87.
    Singer C, Armstrong D, Rosen PP, Schottenfeld D. Pneumocystis carinii pneumonia: A cluster of eleven cases. Ann Intern Med 1975;82:772–777.PubMedGoogle Scholar
  88. 88.
    Chave JP, David S, Wauters JP, van Melle G, Francioli P. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: A cluster of Pneumocystis carinii pneumonia in renal transplant recipients. AIDS 1991;5:927–932.PubMedCrossRefGoogle Scholar
  89. 89.
    Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic diseases. Semin Respir Infect 1992;7:114–121.PubMedGoogle Scholar
  90. 90.
    Israelski DM, Remington JS. Toxoplasmosis in patients with cancer. Clin Infect Dis 1993;17(Suppl. 2):S423–S435.PubMedGoogle Scholar
  91. 91.
    Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 1994;14:241–245.PubMedGoogle Scholar
  92. 92.
    Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: A 20 year experience. Bone Marrow Transplant 1994;13:549–557.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Gary A. Noskin

There are no affiliations available

Personalised recommendations